Download PDF: COMING SOON
Abstract
Gonadotropin-releasing hormone analogs (“puberty blockers”) have rapidly become the preferred method of treatment for childhood gender nonconformity or for teenagers experiencing various levels of gender dysphoria. Use of these drugs raises questions regarding the ability of prepubescent children to give an informed consent to life-altering interventions with unknown future effects. The article argues the use of puberty blockers fails to meet the standard of informed consent.
Keywords: gonadotropin-releasing hormone analogs, puberty blockers, informed consent, gender affirmative model.
This content is restricted to active online subscriptions.
To read the full text or download the PDF please log in or subscribe today.
Cite as: J. Alan Branch, “Does the Use of Puberty-Suppressing Drugs Satisfy the Requirements of Informed Consent?” Ethics & Medicine 38, no. 1–2 (2022): Early Access.
Download PDF: COMING SOON